Merck.com - Research and Development News 
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.Merck & Co., Inc. and Pfizer Enter Worldwide Collaboration Agreement to Develop and Commercialize Ertugliflozin, an Investigational Medicine for Type 2 Diabetes
Dateline City:
WHITEHOUSE STATION, N.J. & NEW YORK
WHITEHOUSE STATION, N.J. & NEW YORK--(BUSINESS WIRE)--Merck & Co., Inc. (NYSE: MRK), known as MSD outside the United States
and Canada (“Merck”), and Pfizer Inc. (NYSE:PFE) today announced that
they have entered into a worldwide (except Japan) collaboration
agreement for the development and commercialization of Pfizer’s
ertugliflozin (PF-04971729), an investigational oral sodium glucose
cotransporter (SGLT2) inhibitor being evaluated for the treatment of
ty...
Source: Merck.com - Research and Development News - April 29, 2013 Category: Pharmaceuticals Authors: hq_site_admin Tags: Research and Development News Corporate News Source Type: news
Merck Announces Breakthrough Therapy Designation for Lambrolizumab an Investigational Antibody Therapy for Advanced Melanoma
Dateline City:
WHITEHOUSE STATION, N.J.
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada,
announced today that the U.S. Food and Drug Administration (FDA) has
designated lambrolizumab (MK-3475) as a Breakthrough Therapy for the
treatment of patients with advanced melanoma. Lambrolizumab is Merck’s
investigational antibody therapy targeting Programmed Death receptor
(PD-1) that is currently being evaluated for the treatment of patients
with advanced melanoma...
Source: Merck.com - Research and Development News - April 24, 2013 Category: Pharmaceuticals Authors: hq_site_admin Tags: Research and Development News Corporate News Source Type: news
Merck to Present Updated Interim Data from Phase II Trial Evaluating Investigational NS3/4A Protease Inhibitor MK-5172 for Chronic Hepatitis C Virus Genotype 1 Infection at the International Liver Congress™
Dateline City:
WHITEHOUSE STATION, N.J.
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada,
today announced the presentation of the latest interim data from a Phase
II, multi-center, randomized, dose-ranging clinical trial evaluating the
safety and antiviral activity of MK-5172, for the treatment of chronic
hepatitis C virus (HCV) genotype 1 infection. MK-5172 is an
investigational, once-daily, oral HCV NS3/4A protease inhibitor that in
preclinical evaluations ...
Source: Merck.com - Research and Development News - April 23, 2013 Category: Pharmaceuticals Authors: hq_site_admin Tags: Research and Development News Corporate News Source Type: news
Merck Enters Agreement with Bristol-Myers Squibb to Conduct a Phase II Clinical Trial Evaluating Combination of Investigational Oral Candidates MK-5172 and Daclatasvir for Chronic Hepatitis C
Dateline City:
WHITEHOUSE STATION, N.J.
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK) today announced it has entered into a non-exclusive
agreement with Bristol-Myers Squibb to conduct a Phase II clinical trial
to evaluate the safety and efficacy of a once-daily oral combination
regimen consisting of Bristol-Myers Squibb’s investigational NS5A
replication complex inhibitor daclatasvir and Merck's investigational
NS3/4A protease inhibitor MK-5172 for the treatment of chronic hepatitis
C virus (HCV) infecti...
Source: Merck.com - Research and Development News - April 22, 2013 Category: Pharmaceuticals Authors: hq_site_admin Tags: Research and Development News Corporate News Source Type: news
Merck Announces FDA Acceptance of Biologics License Application for Investigational Grass Pollen Allergy Immunotherapy Tablet
Dateline City:
WHITEHOUSE STATION, N.J.
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada,
today announced that the Biologics License Application (BLA) for its
investigational Timothy grass pollen (Phleum pratense) allergy
immunotherapy tablet (AIT) has been accepted for review by the U.S. Food
and Drug Administration (FDA). In March, the company also submitted a
BLA to the FDA for its investigational ragweed pollen (Ambrosia
artemisiifolia) AIT.
La...
Source: Merck.com - Research and Development News - March 27, 2013 Category: Pharmaceuticals Authors: hq_site_admin Tags: Research and Development News Corporate News Source Type: news
Merck and Luminex Corporation Enter Agreement to Develop Companion Diagnostic to Support Investigational BACE inhibitor Clinical Development Program for Alzheimer’s Disease
Dateline City:
WHITEHOUSE STATION, N.J. & AUSTIN, Texas
Collaboration to Support Patient Selection for the Clinical Development of MK-8931, Merck’s Lead Investigational Medicine for Alzheimer’s Disease
WHITEHOUSE STATION, N.J. & AUSTIN, Texas--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada,
and Luminex Corporation (NASDAQ:LMNX) have signed a collaboration and
license agreement to develop a companion diagnostic device th...
Source: Merck.com - Research and Development News - March 13, 2013 Category: Pharmaceuticals Authors: hq_site_admin Tags: Research and Development News Corporate News Source Type: news
Merck Provides Update on IMPROVE-IT Trial
Dateline City:
WHITEHOUSE STATION, N.J.
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today said that the Data Safety Monitoring Board (DSMB) of the
IMPROVE-IT trial has completed its planned review of study data and
recommended that the study continue.
The study design calls for the collection of 5,250 clinical endpoints.
Merck remains blinded to the actual results of this analysis and to
other IMPROVE-IT safety and efficacy data.
Lang...
Source: Merck.com - Research and Development News - March 12, 2013 Category: Pharmaceuticals Authors: hq_site_admin Tags: Research and Development News Corporate News Source Type: news
Results from HPS2-THRIVE Study of TREDAPTIVE™ (extended-release niacin/laropiprant) Presented at American College of Cardiology Scientific Sessions
Dateline City:
SAN FRANCISCO
SAN FRANCISCO--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada,
today announced that researchers from the Clinical Trial Service Unit at
Oxford University presented results from the HPS2-THRIVE (Heart Protection
Study 2-Treatment of HDL to Reduce the Incidence
of Vascular Events) study of TREDAPTIVE™(extended-release
niacin/laropiprant) during a late-breaking clinical trials session at
the American College of Cardiology 62nd Annual Scientific
Ses...
Source: Merck.com - Research and Development News - March 9, 2013 Category: Pharmaceuticals Authors: hq_site_admin Tags: Research and Development News Corporate News Latest News Source Type: news
Merck Announces Appointment of Roger M. Perlmutter, M.D., Ph.D., As President of Merck Research Laboratories; Peter S. Kim, Ph.D., to Retire
Dateline City:
WHITEHOUSE STATION, N.J.
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada,
today announced the appointment of Roger M. Perlmutter, M.D., Ph.D., as
executive vice president and president of Merck Research Laboratories
(MRL), effective April 15. Dr. Perlmutter will succeed Peter S. Kim,
Ph.D., who has served in the role since 2003. To ensure a seamless
transition, Dr. Perlmutter and Dr. Kim will work closely together for an
initial period, after ...
Source: Merck.com - Research and Development News - March 7, 2013 Category: Pharmaceuticals Authors: hq_site_admin Tags: Research and Development News Corporate News Latest News Source Type: news
Merck Scientist Daria Hazuda Presents Bernard Fields Lecture at 20th Conference on Retroviruses and Opportunistic Infections (CROI)
Dateline City:
ATLANTA
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced its worldwide head of Antiviral Basic Research and internationally renowned scientist, Daria Hazuda, Ph.D., presented the annual Bernard Fields Lecture yesterday at the opening session of the 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013) in Atlanta, Ga.
Language:
English
Ticker Slug:
Ticker: NYSE ...
Source: Merck.com - Research and Development News - March 4, 2013 Category: Pharmaceuticals Authors: Maria.tortoreto at merck.com Tags: Research and Development News Source Type: news
Merck to Present New Data Analyses of its Investigational Ragweed Pollen and Grass Pollen Allergy Immunotherapy Tablets
Dateline City:
WHITEHOUSE STATION, N.J.
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada,
today announced that researchers will present new data analyses of the
safety and efficacy of the company’s investigational allergy
immunotherapy tablets (AITs) for ragweed pollen (Ambrosia
artemisiifolia) and grass pollen (Phleum pratense) at the
2013 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual
Meeting. The meeting will be held in San Antonio f...
Source: Merck.com - Research and Development News - February 22, 2013 Category: Pharmaceuticals Authors: hq_site_admin Tags: Research and Development News Corporate News Source Type: news
Merck Provides Update on Next Steps for TREDAPTIVE™ (extended-release niacin/laropiprant)
Dateline City:
WHITEHOUSE STATION, N.J.
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada,
today announced the company is taking steps to suspend the availability
of TREDAPTIVE™ (extended-release niacin/laropiprant) tablets
worldwide. TREDAPTIVE is not approved for use in the United States.
Language:
English
Contact HTML:
MerckM...
Source: Merck.com - Research and Development News - January 11, 2013 Category: Pharmaceuticals Authors: hq_site_admin Tags: Research and Development News Source Type: news
Merck Announces FDA Acceptance of Resubmission of New Drug Application for Sugammadex Sodium Injection
Dateline City:
WHITEHOUSE STATION, N.J.
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada,
today announced that the resubmission of the New Drug Application (NDA)
for sugammadex sodium injection has been accepted for review by the U.S.
Food and Drug Administration (FDA). Merck expects the FDA’s review to be
completed in the first half of 2013.
Language:
English
Contact HTML:
...
Source: Merck.com - Research and Development News - January 7, 2013 Category: Pharmaceuticals Authors: hq_site_admin Tags: Research and Development News Source Type: news
Merck Announces FDA Acknowledgement of Resubmission of New Drug Application for Ezetimibe/Atorvastatin Tablets
Dateline City:
WHITEHOUSE STATION, N.J.
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada,
announced today that the U.S. Food and Drug Administration (FDA) has
acknowledged the resubmission of a New Drug Application (NDA) for
ezetimibe and atorvastatin tablets, an investigational combination
medicine. The updated NDA was deemed complete for review after Merck
submitted additional data in response to the FDA’s Complete Response
Letter issued last year.
...
Source: Merck.com - Research and Development News - January 2, 2013 Category: Pharmaceuticals Authors: hq_site_admin Tags: Research and Development News Source Type: news
